LY3532226

DRUG5 trials

Sponsors

Eli Lilly and Company

Conditions

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HealthyObesityOverweight

Phase 1

A Study of LY3532226 in Healthy Participants

CompletedNCT04923269

Eli Lilly and CompanyHealthy

Start: 2021-06-10End: 2021-10-28Updated: 2021-12-17

A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

CompletedNCT05407961

Eli Lilly and CompanyDiabetes Mellitus, Type 2

Start: 2022-06-07End: 2024-01-12Updated: 2024-03-29

A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

CompletedNCT05887999

Eli Lilly and CompanyDiabetes Mellitus, Type 1

Start: 2023-06-12End: 2024-02-21Updated: 2024-03-26

A Study of LY3532226 in Participants With Obesity

CompletedNCT06557356

Eli Lilly and CompanyObesity

Start: 2024-08-16End: 2025-12-12Updated: 2026-01-20

Phase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

RecruitingNCT06143956

Eli Lilly and CompanyObesity, Overweight

Start: 2023-11-17End: 2028-02-01Target: 1481Updated: 2026-09-08